Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | CTRC | Q99895 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8936087 | 1.00 | MAPT (0.47) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL755504 | 0.83 | MAPT (0.45) | MAPTACHESIGMAR1 | |
| SCHEMBL22873345 | 0.83 | MAPT (0.45) | MAPTACHESIGMAR1 | |
| SCHEMBL15648976 | 0.83 | MAPT (0.45) | MAPTACHEHPGDSIGMAR1ALDH1A1 | |
| SCHEMBL3056314 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL15700421 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL3056318 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL3056320 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL6204136 | 0.82 | CHRM2 (0.44) | MAPTCSNK2A2CSNK2BCSNK2A1ABCG2 | |
| SCHEMBL4983527 | 0.78 | EP300 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2022-01-18 | — | — | US | disclosed |
| CN-109415367-B | Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2021-04-16 | — | — | CN | disclosed |
| EP-3478686-B1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-04-15 | — | — | EP | disclosed |
| US-20190241570-A1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241570-A1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| CN-101568543-B | Macrocyclic peptides as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2012-06-06 | — | — | CN | disclosed |
| EP-2437599-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-04-05 | — | — | US | disclosed |
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-04-05 | — | — | US | disclosed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-0659178-A4 | CHIRAL QUINOLONE INTERMEDIATES. | ABBOTT LAB (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0659178-A1 | CHIRAL QUINOLONE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994006766-A1 | CHIRAL QUINOLONE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5252747-A | Chiral quinolone intermediates | ABBOTT LABORATORIES (US) | 1993-10-12 | — | — | US | disclosed |
| US-4210660-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, ESPECIALLY ANTIPSYCOTICS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | MAPT 795/4885CSNK2A2 3476/4885CSNK2B 3389/4885 |
| US-20190241570-A1 | NOVEL DIHYDROPYRROLOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | DPYD, HAVCR2, QDPR | MAPT 3891/4885CSNK2A2 3290/4885CSNK2B 2962/4885 |
| US-11225482-B2 | Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, HAVCR2, QDPR | MAPT 4012/4885CSNK2A2 3259/4885CSNK2B 3202/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | MAPT 3487/4885CSNK2A2 935/4885CSNK2B 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.